for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Roche Gets EU Approval For Chronic Lymphocytic Leukaemia Treatment

March 12 (Reuters) - Roche Holding AG:

* EUROPEAN COMMISSION APPROVES VENCLYXTO PLUS GAZYVARO FOR ADULTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA

* COMBINATION REGIMEN OFFERS A NEW 12-MONTH, FIXED-DURATION, CHEMOTHERAPY-FREE TREATMENT OPTION FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA

* RESULTS OF THE PHASE III CLL14 STUDY ADD TO THE GROWING BODY OF EVIDENCE SUPPORTING THE POTENTIAL OF VENCLYXTO-BASED COMBINATIONS ACROSS MULTIPLE LINES

* DATA SHOWED THAT A FIXED DURATION OF TREATMENT WITH VENCLYXTO PLUS GAZYVARO REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 65% COMPARED TO A CURRENT STANDARD-OF-CARE Source text: bit.ly/2wUPnIP Further company coverage: (Berlin Speed Desk)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up